On Rare Disease Day 2026, Certara experts share how cross-functional innovation, regulatory strategies for rare…
CertaraFebruary 26, 2026
Pharmacokinetics, Safety Profile, and Tolerability of MN-08 Tablets after Single and Multiple Ascending Doses in Healthy Chinese Volunteers
Find out how Phase I study shows dose-related MN-08 exposure, 21–32 h half-life, and good…
CertaraFebruary 25, 2026
Start right, finish strong: Antibody-drug conjugate (ADC) studies for success
Learn how to build regulatory-ready first-in-human (FIH) dose strategies for antibody-drug conjugates (ADCs). Discover how…
CertaraFebruary 23, 2026
FAQs: The ICH M15 guideline and what it means for model-informed drug development
Learn what the ICH M15 guideline means for Model-Informed Drug Development, regulatory credibility, harmonization, and…
CertaraFebruary 18, 2026
Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD)
Prepare for ICH M15 guideline: Learn how to assess model credibility, align terminology, and strengthen…
CertaraFebruary 13, 2026
Pediatric drug development: From “wild west” to model-informed confidence
Model-informed drug development and precision dosing are transforming pediatric programs, from regulatory planning to Bayesian…
CertaraFebruary 11, 2026
QSP in inflammatory bowel disease (IBD): From biomarkers to clinical endpoints, with virtual patients
Certara supports IBD drug development with a QSP model that predicts Mayo score and CDAI…
CertaraFebruary 10, 2026
Pharmacokinetic and toxicological evaluation of AB-CHMINACA in rodents: A comprehensive study
Explore how rodent study reveals 14 h half-life, key metabolites, and dose-dependent toxicity of AB-CHMINACA…
CertaraFebruary 5, 2026
Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants
This study, published in Clinical Pharmacology & Therapeutics (CPT), shows how population pharmacokinetic modeling supports…
CertaraFebruary 2, 2026
